📈 INCA33890 plus SOC therapy was tolerable and elicited responses in patients with MSS CRC in the first-line and third-line settings. @myESMO #ESMO2026 #crcsm #oncology

Full story ➡️: https://www.onclive.com/view/inca33890-plus-soc-elicits-responses-and-is-tolerable-across-in-first--and-third-line-mss-crc